The Novel Costimulatory Programmed Death Ligand 1/B7.1 Pathway Is Functional in Inhibiting Alloimmune Responses In Vivo
Mohamed H. Sayegh(Brigham and Women's Hospital), Alison M. Paterson(Brigham and Women's Hospital), Arlene H. Sharpe(Broad Institute), Anil Chandraker(Brigham and Women's Hospital), Xiaozhi Zhao(Brigham and Women's Hospital), Bruce R. Blazar(University of Minnesota Medical Center), Scott J. Rodig(Brigham and Women's Hospital), Miyuki Azuma(Senju Pharmaceutical (United States)), Vijay K. Vanguri(University of Massachusetts Chan Medical School), Hideo Yagita∥(Juntendo University), Gordon J. Freeman(Dana-Farber Cancer Institute), Leonardo V. Riella(Brigham and Women's Hospital), Susanne Chock(Brigham and Women's Hospital), Tao Liu(Dana-Farber Cancer Institute), Toshihiko Watanabe(Brigham and Women's Hospital), Xueli Yuan(Brigham and Women's Hospital)
Cited by 133
Related Papers
PD-1 and Its Ligands in Tolerance and Immunity
|Annual Review of Immunology|2008|5.3k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|2.9k
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis
|Nature Medicine|2007|2.2k
Identifying ChIP-seq enrichment using MACS
|Nature Protocols|2012|2.1k
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
|The Journal of Experimental Medicine|2009|2k